Terveystalo Calls a Bottom for the Fourth Time — But Its Dental Bet Is Genuinely New

A quarter where every KPI has a minus sign, a CFO's farewell, and a reporting structure rebuilt around the one business that is actually growing

TTALO.HE · Earnings Call · 2026-10-21

The third 'bottom' is not a bottom

Juuso Pajunen, in his sixteenth and final quarterly result as CFO, did not dress the quarter up. “In each and every KPI, you see the negative sign in front of those ones, and it's absolutely not something that we can be happy with.” — Juuso Pajunen, CFO · 2026-10-21 Revenue fell roughly 6%, EBIT fell faster, and full-year adjusted operating profit guidance was cut to EUR 110–120m from the EUR 120–140m range set in July. Net debt to adjusted EBITDA sits at 2.9x against a 3.0x target, inflated by the Hohde acquisition. What makes this more than a bad quarter is the pattern. Terveystalo has now called the turn four times and missed four times. In February the CEO framed the volume weakness as a cycle that would simply roll over: “it's cyclical and then it's sort of upper respiratory morbidity type of impact. And it will, of course, turn around.” — Ville Iho, CEO · 2026-02-13 By April the language hardened into a data claim — “at least our internal data is indicating that we have now bottomed out.” — Juuso Pajunen, CFO · 2026-04-24 In July the guidance came down and the connected employee numbers recovery slid to year-end: “Rather, the increase is expected to time at the year-end.” — Ville Iho, President and CEO · 2026-07-17 Today it slid again, to the first quarter of 2027, with an explicit warning that Q4 gets no benefit from it at all. The company's own keyword history captures the drift. 'Number of connected employees' was a top-five theme in late 2025; it has now fallen out of the top thirty entirely. In its place sits muted demand — a description of the environment rather than a lever the company controls. That is the tell. When a management team stops quantifying the thing it promised to fix and starts characterising the weather instead, you are watching a thesis get repriced.

Our earlier expectation was that the ramp-up from the summer season to first sort of actual active season for the health care services would be steeper and higher. But now we are basically basing our Q4 forecasts and assumptions on the lower volumes that we got during September. We are prudent with our forecasting.
Ville Iho, CEO · 2026-10-21

One detail worth flagging: the occupational health decline is not uniform. Management disclosed for what appears to be the first time that roughly two thirds of connected employees are large customers and one third SMEs — and the large accounts are now growing again while SMEs still churn net negative. The problem is narrow, but the segment is not.

What is actually new: Oral Health, and a reporting structure that admits it

The single most-changed thing at Terveystalo is not in the P&L. It is the keyword slate. Oral Health is the company's number-one theme this quarter by a wide margin; ARC strategy is second. Neither existed as a dominant theme a year ago, and the Hohde acquisition has closed and is contributing EUR 5.5m of the EUR 6.2m in dental revenue growth — meaning there is genuine organic growth underneath the deal, in a quarter where almost nothing else grew. Ville Pesonen, Hohde's founder and now SVP Oral Health, put a number on the prize: a Finnish dental market of about EUR 1.3bn including public, roughly EUR 700m private, historically growing 2% a year and expected to run at about 5%. Terveystalo now fields 1,500 dental professionals across 77 sites — 63 clinics and 14 laboratories. Juuso framed the deal at EUR 88m enterprise value, roughly 8x EBITDA with EUR 4m of synergies, and noted the integration is already delivering best-of-both-worlds learning on supply management and recall. More telling still: from January 2027 the company will report four segments — Healthcare Services, Oral Health, Public Partnerships and Sweden. A management team that redraws its reporting lines around a business is telling you where it believes the equity story lives. It is also, conveniently, a way to let a shrinking occupational health core hide inside a broader Healthcare Services line. The offsetting frustration is Silmaasema, the optical chain acquisition. Closing has slipped — management now concedes this year is less likely than Q1 2027 — and the Capital Markets Day has been pushed from December to next spring precisely because the combined picture cannot yet be shown. Note the funding structure: partly equity, partly debt. With leverage already at 2.9x, an equity component into a delayed deal is a dilution risk that received almost no airtime on this call.

The obesity pilot nobody asked about

Buried in the strategy section is the most forward-looking thing Terveystalo has said in years. The Wellby platform — a digitally-driven continuous care offering — launched in pilot in Q3, with obesity management as its first service and a full platform launch due in Q4. This is a clinic network trying to sell a subscription-shaped, high-frequency product instead of waiting for episodic patients to walk in, and it maps directly onto one of the few genuinely warm demand pools in the market: the global tape shows patients with obesity as an advancer across the 30-, 90- and 360-day windows, led by names like Regeneron, Viking and Novo. Terveystalo is not competing on molecules; it is competing for the care delivery around them. That is a different, and cheaper, way to own the same demand. The ARC pillars around it — transparent service packages, easier buying, transparent pricing — are the maturing of the fixed price narrative that topped the July call. Ville was candid that elective-adjacent services respond to packaging regardless of category, citing orthopaedics, GP and gynaecology. The company is also pushing AI into back office via its Nova programme and a '10x' efficiency effort on digital appointments.

The trade

Strip out the noise and you have a small-cap (about EUR 1.0bn) with a genuine operating leverage story that is currently running in reverse. sales mix turned negative on weak laboratory and diagnostics volumes, morbidity ran 15% below prior year, and variable costs were cut only as fast as revenue fell — good defence, no offence. The bull case requires connected employees to grow in Q1 2027, dental to keep compounding, Silmaasema to close without a dilutive surprise, and Finnish consumer confidence to stop teasing. That is four things, and only one of them is fully in management's hands. The honest summary is that Terveystalo has stopped selling a cyclical recovery and started selling a structural story — consumer health, dental, digital continuous care. That is a better story. But it is a story that now needs the new CFO to deliver a first quarter of growth, and the market has heard the opposite promise three times already.